Bond.az reports that Immunocore announced updated Phase 1/2 trial results for brenetafusp in heavily pretreated advanced melanoma patients.
The trial enrolled 66 patients. Median overall survival was 14.3 months, with a 6-month survival rate of 87% and a 12-month survival rate of 57%.
Disease control rate reached 52%, and overall response rate was 12%. The 160 microgram dose showed numerically higher benefits.
Common adverse events included cytokine release syndrome (56%), rash (44%), pyrexia (44%), and chills (38%). Grade 3-4 events included transient decreased lymphocyte count (25%).
